Literature DB >> 8258189

Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.

G Los1, L Tuyt, M van Vugt, J Schornagel, H M Pinedo.   

Abstract

In the present study, cisplatin (cDDP) and carboplatin (CBDCA) were combined in different in vitro and in vivo assays to determine whether combined cDDP and CBDCA treatment would eventually lead to a better antitumor response. Co-incubation of CC531 cells with cDDP and CBDCA led to higher intracellular Pt concentrations (30.5 +/- 3.4 ng Pt/10(6) cells) than did cDDP (16.9 +/- 9.4 ng Pt/10(6) cells) or CBDCA (1.28 +/- 0.72 ng Pt/10(6) cells) incubation alone. In survival assays an additive cell kill was seen after combined treatment with cDDP and CBDCA. DNA binding experiments using isolated salmon-sperm DNA exposed to the drugs separately or in combination were in agreement with the survival studies (for cDDP a binding of 12.42 micrograms Pt/mg DNA; for CBDCA, 0.49 microgram Pt/mg DNA; and for combined CBDCA and cDDP, 12.9 micrograms Pt/mg DNA at 76 h). Toxicity studies in rats treated with cDDP plus CBDCA required a dose reduction for cDDP amounting to 20% of the MTD, whereas the CBDCA dose could be maintained. Pharmacokinetics studies showed higher AUCs and t1/2 beta in plasma as well as the peritoneal cavity after combined treatment with cDDP and CBDCA (both given i.p.) or following cDDP given i.p. and CBDCA given i.v. Pt concentrations in peritoneal tumors corresponded with these observations, with higher Pt concentrations following combined treatment than after single-agent injection. In addition, combined administration of cDDP i.p. and CBDCA i.v. led to higher Pt concentrations in peritoneal tumors than did administration of both drugs i.p. (3.93 +/- 0.9 vs 2.76 +/- 0.2 mg Pt/g tissue). The higher Pt concentrations in the peritoneal tumors after combined treatment was associated with a significantly better antitumor response in comparison with that observed after single-agent treatment (a growth delay of 30.2 +/- 5.6 days for cDDP i.p. plus CBDCA i.v. vs 16.1 +/- 5.4 days for cDDP alone and 10.8 +/- 4.2 days for CBDCA alone).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258189     DOI: 10.1007/bf00685885

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  40 in total

1.  Summary of symposium: Biology and therapy of ovarian cancer.

Authors:  R F Ozols; T C Hamilton; W J Hoskins; R C Bast; R C Young
Journal:  Semin Oncol       Date:  1991-06       Impact factor: 4.929

Review 2.  Toxic effects of cis-dichlorodiammineplatinum(II) in man.

Authors:  D D Von Hoff; R Schilsky; C M Reichert; R L Reddick; M Rozencweig; R C Young; F M Muggia
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

Review 3.  Intraperitoneal chemotherapy: a review.

Authors:  D E Brenner
Journal:  J Clin Oncol       Date:  1986-07       Impact factor: 44.544

4.  Pharmacokinetics of carboplatin after i.v. administration.

Authors:  F Elferink; W J van der Vijgh; I Klein; J B Vermorken; H E Gall; H M Pinedo
Journal:  Cancer Treat Rep       Date:  1987-12

5.  In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines.

Authors:  R P Perez; K M Perez; L M Handel; T C Hamilton
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Experimental and clinical results with intraperitoneal cisplatin.

Authors:  W W ten Bokkel Huinink; R Dubbelman; E Aartsen; H Franklin; J G McVie
Journal:  Semin Oncol       Date:  1985-09       Impact factor: 4.929

7.  Pharmacologic reversal of drug resistance in ovarian cancer.

Authors:  R F Ozols
Journal:  Semin Oncol       Date:  1985-09       Impact factor: 4.929

8.  Pharmacokinetics of carboplatin after intraperitoneal administration.

Authors:  F Elferink; W J van der Vijgh; I Klein; W W ten Bokkel Huinink; R Dubbelman; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.

Authors:  G A Omura; B N Bundy; J S Berek; S Curry; G Delgado; R Mortel
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

10.  Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy.

Authors:  G Los; E M Verdegaal; P H Mutsaers; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more
  2 in total

1.  Staged laparoscopic adjuvant intraperitoneal chemohyperthermia after complete resection for locally advanced colorectal or gastric cancer: a preliminary experience.

Authors:  Elie Chouillard; Toufic Ata; Bernard De Jonghe; Léon Maggiori; Nada Helmy; Yvan Coscas; Hervé Outin
Journal:  Surg Endosc       Date:  2008-05-07       Impact factor: 4.584

2.  Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin.

Authors:  G Los; M J van Vugt; H M Pinedo
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.